Clinical trial · Interventional
Acupuncture for People Experiencing Period Loss Due to Chemotherapy
Acupuncture for Adolescent and Young Adult Cancer Patients: (AcuAYA)
NCT06915116CI-TRIAL-00122288recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to find out whether it is practical (feasible) to use acupuncture to treat period loss (amenorrhea) caused by chemotherapy treatment in people with cancer. The researchers will look at how many participants enroll and complete the study. The researchers will also study how treatment with acupuncture affects the amount of time for the menstrual cycle to return and symptoms and quality of life related to amenorrhea.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Period Problem | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Acupuncture | Procedure | — | UNRESOLVED |
| No Acupuncture | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Acupuncture group
- description
- Participants in the acupuncture group will receive 12 acupuncture treatments over 12 weeks during the study.
- interventionNames
- Procedure: Acupuncture
- type
- ACTIVE_COMPARATOR
- label
- Wait-list Control (WLC)
- description
- Participants in the wait-list control group will be put on a wait-list and have the option to receive the same acupuncture treatment as the acupuncture group after a 16-week waiting period. The 16-week waiting period will begin on the day that the WLC participant completes their baseline lab draw.
- interventionNames
- Other: No Acupuncture
Primary outcomes (2)
- measure
- Enrollment rate
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 15 Years
- Maximum age
- 40 Years
Show eligibility criteria text
Inclusion Criteria: * English speaking woman between the ages of 15 and 40 * History of stage I, II, or III cancer OR stage IV or unstaged hematologic malignancy (e.g. lymphoma, leukemia, myeloma) that is stable, as assessed by care team * Premenopausal status with regular menstruation at the time of diagnosis by patient report * Completed cytotoxic chemotherapy within the past year * Premenopausal status with regular menstruation at the time of diagnosis by patient report for females ages 18 or older * Report cessation of menses during or after chemotherapy and have not experienced menses recovery at the time of enrollment. * Have reached menarche prior to therapy or during therapy for females between 15 and 17 years old * Patient meets at least one of the following: * Reports cessation of menses during or after chemotherapy and have not experienced menses recovery at the time of enrollment and has been without menses for at least 3 months 64 following the completion of cytotoxic chemotherapy; OR * Is receiving ovarian suppression therapy (e.g., leuprolide \[Lupron\] or goserelin \[Zoladex\]) or hormonal contraceptive drugs, regardless of menstrual status, and report persistent (≥3 months), moderate-to- severe menopause-related symptoms, defined as a score of ≥4 on a 0-10 scale for at least one MENQOL item during eligibility screening. * Willing to adhere to all study-related procedures, including randomization to one of the two possible arms: acupuncture and WLC Exclusion Criteria: * Had been pregnant or lactating within 3 months prior to enrollment * History of hysterectomy or bilateral oophorectomy * Ongoing or planned radiation or surgery within 4 months from randomization * Use of acupuncture for menses recovery within 3 months of enrollment * Had been or will be receiving ovarian suppression medicine, such as leuprolide (Lupron) and goserelin (Zoladex), or hormonal contraception drugs within 3 months of enrollment or during the study period
References
Publications (0)
Data not yet available
No reference posted for this study.